Measles Vaccination in HIV-Infected Children: Systematic Review and Meta-Analysis of Safety and Immunogenicity by Scott, Pippa et al.
S U P P L E M E N T A R T I C L E
Measles Vaccination in HIV-Infected Children:
Systematic Review and Meta-Analysis of Safety
and Immunogenicity
Pippa Scott,1 William J. Moss,2 Zunera Gilani,2 and Nicola Low1
1Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine, University of Bern, Switzerland; and 2Department of
Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
Background. Measles control may be more challenging in regions with a high prevalence of HIV infection.
HIV-infected children are likely to derive particular benefit from measles vaccines because of an increased risk of
severe illness. However, HIV infection can impair vaccine effectiveness and may increase the risk of serious adverse
events after receipt of live vaccines. We conducted a systematic review to assess the safety and immunogenicity of
measles vaccine in HIV-infected children.
Methods. The authors searched 8 databases through 12 February 2009 and reference lists. Study selection and
data extraction were conducted in duplicate. Meta-analysis was conducted when appropriate.
Results. Thirty-nine studies published from 1987 through 2008 were included. In 19 studies with information
about measles vaccine safety, more than half reported no serious adverse events. Among HIV-infected children,
59% (95% confidence intervals [CI], 46–71%) were seropositive after receiving standard-titer measles vaccine at
6 months (1 study), comparable to the proportion of seropositive HIV-infected children vaccinated at 9 (8 studies)
and 12 months (10 studies). Among HIV-exposed but uninfected and HIV-unexposed children, the proportion
of seropositive children increased with increasing age at vaccination. Fewer HIV-infected children were protected
after vaccination at 12 months than HIV-exposed but uninfected children (relative risk, 0.61; 95% CI, .50–.73).
Conclusions. Measles vaccines appear to be safe in HIV-infected children, but the evidence is limited. When
the burden of measles is high, measles vaccination at 6 months of age is likely to benefit children of HIV-infected
women, regardless of the child’s HIV infection status.
Approximately one million HIV-infected children live
in the 47 countries with the highest burden of mea-
sles [1, 2]. Measles occurs at a younger age and is as-
sociated with an increased risk of severe illness and
death in HIV-infected children [3, 4]. Measles vaccine,
however, has the potential to cause serious adverse
events in immunocompromised persons due to repli-
cation of measles vaccine virus [5, 6]. Progressive HIV-
related immunosuppression can also impair vaccine
effectiveness. In healthy immunocompetent persons,
adverse events after measles vaccination are usually mild
and transient, and seroconversion rates of.90% can be
achieved [7, 8].
The World Health Organization (WHO) recom-
mended in 2004 that, unless severely immunocompro-
mised, HIV-infected infants should receive measles
vaccine at 6 months of age, followed by another dose at 9
months [8]. In practice, this is difficult to achieve be-
cause the child’s HIV infection status is usually un-
known during early infancy [3]. The WHO Global
Advisory Committee on Vaccine Safety (GACVS) sub-
group on immune deficiencies commissioned this sys-
tematic review and contributed to formulating research
questions to reassess current recommendations. The
objective was to examine the safety and immunogenicity
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of measles vaccine in HIV-1–infected children to assess the
balance of benefits and risks.
METHODS
Information Sources and Search
We searched Medline, Embase, the Cochrane Library, African
Index Medicus, the Indian Medlars Centre, Latin American
and Caribbean Health Sciences, AIDSLine, and Conference on
Retroviruses and Opportunistic Infections abstracts for articles
published from the earliest date available through February
2009. We used key words or subject headings for ‘‘measles
vaccine’’ or ‘‘measles immunization’’ in combination with
‘‘HIV,’’ adapted to each database. We screened bibliographies
of selected review articles and contacted experts to identify
additional publications or studies. There were no language
restrictions.
Eligibility Criteria
Eligible study designs were randomized controlled trials (RCTs)
or quasi-RCTs, controlled clinical trials, cohort, case-control,
or cross-sectional studies, comparing measles-vaccinated HIV-
infected children with measles-vaccinated HIV-uninfected
children (either HIV-unexposed or HIV-exposed but un-
infected) or HIV-infected children not vaccinated against
measles. To assess safety, we also considered case reports that
might identify rare adverse events and studies of measles vac-
cination of HIV-infected children without a comparison group.
The population of interest was children 0–15 years of age,
either with confirmed HIV-1 infection or who were exposed to
HIV-1 (ie, born to an HIV-1–infected mother) with or without
confirmed infection. The intervention was measles vaccination
with a licensed, single- or combined-antigen vaccine. Outcomes
relating to vaccine safety, immunogenicity, or clinical measles
were required to be reported. Studies meeting all criteria were
included.
Study Selection
Two reviewers (PS and NL) independently evaluated all re-
trieved articles sequentially by title, abstract, and full text. Those
considered by one or both reviewers to potentially match
inclusion criteria were retained at each stage.
Data Collection and Analysis
Two reviewers (PS and ZG) independently extracted data onto
piloted structured forms, including information on study pop-
ulation, vaccine types, sample size, loss to follow-up, outcomes,
and source of funding. We also extracted information about
predefined study characteristics that could result in bias, such
as loss to follow-up, lack of blinding in the assessment of out-
comes, or differences between groups in the interval between
vaccination and serological assessment.
We assessed whether safety outcomes were reported and
numbers and types of serious adverse events, including deaths.
For measles vaccine immunogenicity, we extracted data on
laboratory assays and definitions of serological responses, as well
as results. Most studies reported seropositivity after vaccination,
but some reported seroconversion (change from seronegative to
seropositive or 4-fold increase in titer). We therefore used
a composite outcome for serological response, using seroposi-
tivity when available and seroconversion otherwise, based on
definitions provided by the authors. We considered children to
be HIV infected if they met the definition for HIV infection
used in the study in which they participated. Data were entered
in EpiData (EpiData Association) by each of the reviewers.
Discrepancies were resolved by consensus, with a third reviewer
(NL) acting as arbiter.
We calculated the percentage seropositive with exact bino-
mial 95% confidence intervals (CIs) separately for each com-
parison group in each study and displayed these in forest plots.
Serological responses in HIV-infected children were compared
with those of available comparison groups in each study with
use of relative risks (RRs) and 95% CIs. Data were combined,
when appropriate, using DerSimonian and Laird random-effects
meta-analysis [9]. We quantified between-trial heterogeneity
with use of the I2 statistic [10]. Meta-analysis was considered to
be inappropriate when the I2 statistic exceeded 50% or a single
study contributed to $2 estimates within strata. Between-trial
heterogeneity was first explored by stratifying results by age at
vaccination (6 months, 9 months, and $12 months) and then
examining heterogeneity within strata. Forest plots of study
results were also stratified by serological cutoff point, serological
test, interval between vaccination and serology, and receipt of
highly active antiretroviral therapy (HAART), and variation
between results was assessed visually. Detailed exploration of
heterogeneity by meta-regression was not possible because data
from 1 study that involved vaccination at different ages [11]
would have appeared multiple times. Differences between the
results of small and large comparative trials were assessed by
visual inspection of funnel plots and with a statistical test for
asymmetry [12] for outcomes reported by $10 trials. Analyses
were conducted using Stata, version 10 (StataCorp). The study
protocol, search strategy, and criteria for the assessment of the
risk of bias are available on request from the authors.
RESULTS
Description of Studies Included
The searches identified 723 potentially relevant articles (Figure 1).
Most ineligible studies were excluded on the basis of information
in the title or abstract. We included 39 articles published from
1989 through 2008 in the review (Table 1). There were 23 articles
with comparison groups that reported data from 25 separate
study populations. All reported on immunogenicity [11, 13,
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19–25, 29–33, 36, 37, 39, 42, 45–49], and 10 (11 study pop-
ulations) reported on adverse events [11, 23, 24, 25, 30, 36, 37, 39,
42, 47] (Figure 1). In total, 4520 children in comparative studies
were vaccinated against measles. Of these, 716 were HIV infected,
1312 were HIV exposed but uninfected, and 1632 were HIV
unexposed. There were 860 vaccinated children in 2 studies in
which the numbers vaccinated in each comparison group were
not provided [23, 39]. Twenty-three studies were available for
examining the comparison of serological responses in measles-
vaccinated HIV-infected children with measles-vaccinated
HIV-uninfected children (either HIV unexposed or HIV ex-
posed but uninfected) [11, 13, 20, 21, 23–25, 29–33, 36, 37, 39,
42, 45–49]. Two of these studies also included a comparison
between measles-vaccinated HIV-infected children and HIV-
infected children either not vaccinated or not revaccinated
against measles [29, 36]. In addition, 1 study restricted to HIV-
infected children compared vaccination at 6 and 12 months
with vaccination at 12 months only [22], and 1 study com-
pared seroconversion in HIV-infected children receiving or not
receiving HAART [19].
Noncomparative studies examining only HIV-infected chil-
dren were included in the assessment of measles vaccine safety
(Figure 1). We included 15 articles (reporting data from 11
studies) published from 1987 thtough 2008 [14–18, 26–28,
34, 35, 38, 40, 41, 43, 44] and data reported from 2 of the
comparative studies that involved prospective revaccination of
only HIV-infected children (referred to as substudies) [33, 45].
These 13 studies involved at least 515 measles-vaccinated HIV-
infected children [14, 16– 18, 26 27, 33– 35 38 40 43 45], because
the number vaccinated was unclear in 2 studies [40, 43]. We
also included a case report of a child in the United Kingdom in
the assessment of measles vaccine safety only [6].
Potential for Bias
There were 7 prospective cohort studies [11, 23, 29, 30, 37, 39,
47], 12 cross-sectional or retrospective cohort studies [13, 19, 20,
24, 31–33, 36, 45, 46, 48,49], and 1 RCT [22]. The study design
in 5 studies (reported in 3 articles) was not clear [21, 25, 42].
In prospective studies and the RCT, 44%–100% of vaccinated
children contributed to the immunogenicity analyses, with
.75% contributing in 5 studies [11, 22, 29, 37, 47]. Only 3 of
25 studies reported blinding in the assessment of outcomes re-
lated to either the children’s HIV infection or vaccination status
[23, 30, 31]. The interval between vaccination and serological
assessment was reported to be similar between groups in only
2 studies [31, 48]; in 7 studies, the interval was not reported but
was likely to be similar [11, 23, 29, 30, 42, 45, 47]. Details of all
items assessed can be seen in Supplementary Table 1.
Smaller trials tended to show lower serological responses than
larger trials in HIV-infected children, compared with HIV-
exposed but uninfected children (P 5 .015 from test for funnel
plot asymmetry in the only comparison containing .10 trials).
This finding persisted in studies in which children were vacci-
nated at 9 months (8 studies; P 5 .019) but not in which chil-
dren were vaccinated at 6 months (3 studies; P 5 .308) or $12
months (5 studies; P 5 .442) of age.
Measles Vaccine Safety
More than 1200 HIV-infected measles-vaccinated children were
included in 39 comparative and noncomparative studies as-
sessed for adverse events (number unclear in 6 studies [23, 25,
32, 39, 40, 43]). We did not identify any study that explicitly
reported measles inclusion body encephalitis, giant cell pneu-
monia, or thrombocytopenia in an HIV-infected child. Only 19
studies, involving at least 630 children, made explicit reference
to adverse events (Table 2). In 7 studies, there was an explicit
statement about the absence of adverse events in HIV-infected
children [17, 24, 25, 26, 27, 33, 38]. Seven studies had similar
statements but also reported results that made interpretation
difficult (eg, that hospitalizations or deaths occurred among
study children) [23, 30, 36, 40, 42, 47]. The remaining 5 studies
reported that deaths or other serious adverse events occurred
among study children [6, 11, 34, 37, 39].
Figure 1. Flow Chart of Study Selection. AIM, African Index Medicus;
CROI, Conference on Retroviruses and Opportunistic Infections; IndMed,
Indian Medlars Centre; LILACs, Latin American and Caribbean Health
Sciences.
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Table 1. Description of Characteristics of Included Studies
Study
Study
design Country
Study setting and
population
Age at last
vaccination
(HIV-infected) Vaccine used
Groups
examineda
Outcomes
reported
Number
measles
vaccinated
Interval between
vaccination and
serology
(HIV-infected)
Al-Attar
1995 [13]
Cross-sect./
retrospec-
tive cohort
USA Children at HIV clinic,
mothers HIV-positive
or high risk of being
HIV-infected
1.2–2.3yr
(median 1.33yr)
Strain NR,
preparation NR
1,3,4b S0 I4 I5 M1 56 1mo–6.7yr
(mean 1.6yr)
Arpadi
1996 [14]
(& Arpadi
1992 [15])
Cross-
sectional
USA Perinatally HIV-infected
children, 9-168mo at
time of study
Unclear.
Min. age at first
dose 6mo
(median 14mo)
Strain NR,
monovalent and
MMR used
1 S0 P1 I0 M0 81 NA
Aurpibul
2006 [16]
Cross-
sectional
Thailand Children on HAART,
.5yr, CD4.15% after
immunosuppression
below this, unclear if
vaccinated before or
while on HAART
Unclear Strain NR,
preparation NR
1 S0 I0 M0 85 NA
Aurpibul
2007 [17]
Prospective
cohort
Thailand Children on HAART,
.5yr, CD4.15%,
measles seronegative
Assume around
age tested
negative in
previous study:
mean 9.9yrs
(SD 2.7yr)
Schwarz, MMR 1 S1 S2 P1 I0 M0 51 NA
Bekker
2006 [18]
Prospective
cohort
Nether-
lands
Children on HAART,
,18yr
First dose, n53:
approx. 14mo
Revaccination,
n515: median
7.3yr
(IQR 4.2–9.0yr)
Strain NR, MMR 1 S0 I0 M0 18 NA
Berkel-
hamer
2001 [19]
Cross-sect./
retrospec-
tive cohort
USA Children’s hospital,
perinatally HIV-infected
,12yr, untreated, non-
HAART or HAART
regimens
3.9–11yr
(mean 7.1yr)
Strain NR, MMR 1,4c S0 I2 M1 28 HAART: 1–4mo
(median 2mo)
No HAART:
1–9mo
(median 3mo)
Bren˜a
1993 [20]
Cross-sect./
retrospec-
tive cohort
USA Hospital pediatric HIV
program
1.2–3yr
(median 1.3yr)
Strain NR, MMR 1,3 S0 I1 I5 M1 33 1mo–3.5yr
(median 2mo)
Brunell
1995a [21]
Unclear USA Perinatally HIV-infected
infants; source of con-
trols unclear
Min. 1.2yr Strain NR, MMR
(MMRV in some
controls)
1,2 S0 I1 I5 M0 30 2mo–2.3yr
(median 7mo)
Brunell
1995b [21]
Unclear USA Children 1.5–9yr;
source unclear
0.7–2.2yr
(median 1.3 yr)
Strain NR, MMR 1,2 S0 I5 M1 66 .75mo–10.6yr
(median 2.4yr)
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Table 1. (Continued)
Study
Study
design Country
Study setting and
population
Age at last
vaccination
(HIV-infected) Vaccine used
Groups
examineda
Outcomes
reported
Number
measles
vaccinated
Interval between
vaccination and
serology
(HIV-infected)
Chandwani
1998 [22]
RCT Unclear Infants born to HIV-
infected mothers
Approx. 1yr Strain NR,
preparation NR
1,4d S0 P1 I4 M0 110 Approx. 1.5mo
Cutts 1993
[23]
Prospective
cohort
Zaire Perinatal HIV trans-
mission study, infants
born to HIV-infected or
-uninfected mothers
Approx. 6mo
(mean 0.5yr, all
groups)
High-titer E-Z,
monovalent
1,2,3 S1 S2 S3 I3 M1 475 Approx. 3mo
Echeverria
Lecuona
1996 [24]
Cross-sect./
retrospec-
tive cohort
Spain Infants of HIV-infected
mothers born and
followed up at study
hospital
Approx 1yr Strain NR,MMR 1,3 S1 S2* P1 I1
M0
40 Approx. 1–2yr
Embree
1989 [25]
Unclear Kenya Perinatal HIV trans-
mission study
Unclear Strain NR, prep-
aration NR
1,3 S1 S2* I4 M1 159 Unclear
Fernandez-
Ibieta 2007
[26]
Retrospec-
tive cohort
Spain Immune-deficiency
unit, children 1.5–19yr
Unclear Strain NR, MMR 1 S1 S2* I0 M0 55 NA
Frenkel
1994 [27]
(& Frenkel
1992 [28])
Cross-sec-
tional &
prospective
cohort
USA Children 1.4–12yr, 80%
on ART, HIV-infected
and symptomatic
Unclear Strain NR, MMR 1 S1 S2* I0 M0 10 NA
Goon 2001
[6]
Case report UK HIV-infected child 14mo Edmonston
strain, MMR
1 S1 S2 S3 I0 M1 1 NA
Helfand
2008 [11]
Prospective
cohort
Malawi Health center, children
attending for routine 14
week immunization
visits
Approx. 9mo E–Z, monovalent 1,2,3 S1 S2 S3 I1 M0 857 included
(1444 total)
Approx.
3mo
Hilgartner
2001 [29]
Prospective
cohort
USA Cohort study,
hemophiliac children
Min. 6mo Strain NR,
preparation NR
1,2,4e S0 P1 I5 M0 34 Approx.
3–9mo
Lepage
1992 [30]
Prospective
cohort
Rwanda Infants of HIV-infected
or HIV-uninfected
mothers
.48–.84yr
(median .51yr)
High-titer,
E–Z, monovalent
1,2,3 S1 S2 S3 I1 I3
I5 M1
372 Approx.
3mo
Lindgren-
Alves 2001
[31]
Cross-sect./
retrospec-
tive cohort
Brazil HIV centre, perinatally
infected children; teach-
ing hospital
controls
Unclear Strain NR,
preparation NR
1,2 S0 I4 I5 M0 50 median 1.4yr,
mean 2.45yr
(SD 2.6yr)
Lyamuya
1995 [32]
Cross-sect./
retrospec-
tive cohort
Tanzania Children at mother and
child health clinics
Min. all groups
.25yr
(median .75yr)
Schwarz,
preparation NR
1,3 S0 I4 I5 M0 NR Unclear, tested
at up to 5yr
Marczynska
2001 [33]
Cross-sect./
retrospec-
tive cohort
Poland Medical university,
HIV-infected children on
HAART; HIV-uninfected
comparison group,
unclear
Unclear Schwarz, both
monovalent and
MMR used
1,2 S0 I1 M0 38 3mo–13yr
(mean 3.1yr)
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Table 1. (Continued)
Marczynska
2001 [33]
(substudy)
Prospective
cohort
Poland Children revaccinated if
measles antibody
negative
5–8yr Schwarz, MMR 1 S1 S2* I0 M0 9 NA
McLaughlin
1988 [34]
Retrospec-
tive cohort
USA Children ,12yr, vacci-
nated before HIV di-
agnosis
Unclear Strain NR, both
monovalent and
MMR used
1 S1 S2 S3 I0 M0 70 NA
Melvin
2003 [35]
Retrospec-
tive cohort
USA Children perinatally HIV-
infected; 1st dose be-
fore HAART, revaccina-
tion on HAART
3–14yr
(median 7yr)
Edmonston
strain, MMR
1 S0 I0 M0 18 NA
Molyneaux
1993 [36]
Cross-sect./
retrospec-
tive cohort
UK Perinatal HIV trans-
mission study
Min. 1yr Strain NR, both
monovalent and
MMR used
1,3,4f S1 S2 I1 M0 70 Approx. 3–9mo
Moss 2007
[37]
Prospective
cohort
Zambia Infants attending a pub-
lic health care facility
Approx. 9mo E–Z, preparation
NR
1,2,3 S1 S2 S3 I1 I3
I5 M1
441 Approx. 1–6mo
Ndikyeze
1987 [38]
Cross-sec-
tional
Rwanda Children 8–19mo HIV vaccinated
before 12mo
Strain NR, prep-
aration NR
1 S1 S2* I0 M0 3 NA
Oxtoby
1989 [39]
Prospective
cohort
Zaire Infants with HIV-in-
fected or -uninfected
mothers
Approx. 9mo Strain NR, prep-
aration NR
1,2,3 S1 S2 S3 I2 M0 954 Approx. 1yr
Palumbo
1992 [40] (&
Hoyt
1992 [41])
Prospective
cohort and
retrospec-
tive case-
finding
USA Children approximately
1–10yr
Unclear Edmonston
strain, MMR
1 S1 S2 S3 I0 M1 92 NA
Rudy
1994a [42]
Unclear USA Special immunology
clinic, infants vacci-
nated at ,12mo
6mo–1yr Strain NR,
monovalent
1,3 S1 S2 I4 M0 35 Approx. 1–3mo
Rudy
1994b [42]
Unclear USA Special immunology
clinic, children vacci-
nated at .12mo
1yr–1.3yr Strain NR, MMR 1,3 S1 S2 I4 M0 26 Approx. 1–3mo
Ruel
2008 [43]
(& Ruel
2007 [44])
Prospective
cohort
Uganda Children 1–10y, unclear
if ART
Unclear Strain NR, prep-
aration NR
1 S0 P1 I0 M0 11 NA
Takano
2003 [45]
Cross-sect./
retrospec-
tive cohort
Brazil Pediatric AIDS clinic Min. 1yr Strain NR, MMR 1,2 S0 I5 M0 139 Approx. 1–3mo
Takano
2003 [45]
(substudy)
Prospective
cohort
Brazil Children without pro-
tective measles anti-
body, all on HAART
Unclear Strain NR, MMR 1 S0 I0 M0 12 NA
Tejiokem
2007 [46]
Cross-sect./
retrospec-
tive cohort
Came-
roon, CAR
4 pediatric care centers,
infants with HIV-in-
fected mothers
9mo–1.3yr Strain NR, prep-
aration NR
1,3 S0 I1 I5 M0 127 3.9mo–2.6yr
(median 1.4yr, all)
M
easles
V
accin
atio
n
in
H
IV
-In
fected
C
h
ild
ren
d
JID
2011:204
(S
u
p
p
l
1)
d
S169
Table 1. (Continued)
Study
Study
design Country
Study setting and
population
Age at last
vaccination
(HIV-infected) Vaccine used
Groups
examineda
Outcomes
reported
Number
measles
vaccinated
Interval between
vaccination and
serology
(HIV-infected)
Thaithu-
myanon
2000 [47]
Prospective
cohort
Thailand Infants of HIV-infected
mothers
Approx. 9mo Schwarz, mono-
valent
1,3 S1 S2 S3 I2 I5
M1
33 Approx. 3mo
Waibale
1999 [48]
Cross-sect./
retrospec-
tive cohort
Uganda Pediatric clinic and pe-
diatric HIV clinic, infants
6mo–2.2yr
(median 0.8yr)
Strain NR,
monovalent
1,3 S0 I1 I5 M0 243 2.7mo–2.4yr
(median 14mo)
Walter
1994 [49]
Cross-sect./
retrospec-
tive cohort
USA Pediatric infectious dis-
ease clinic, HIV-infected
or child of HIV-infected
mother
Mean 1.7yr Strain NR, MMR 1,3 S0 I4 I5 M0 104 Mean 3.1mo
NOTE. CAR, Central African Republic; mo, months of age; Max, maximum; Min, minimum; MMR, measles, mumps, rubella vaccine; MMRV, measles, mumps, rubella, varicella vaccine; NA, not applicable; NR, not
reported; yr, years of age;
a Groups: 1, HIV-infected (vaccinated); 2, HIV-unexposed (vaccinated); 3, HIV-exposed but uninfected (vaccinated); 4, other;
b ‘‘other’’ group in Al-Attar et al are HIV-infected children, infected via transfusion (group 1 are HIV-infected by vertical transmission);
c ‘‘other‘‘ group in Berkelhamer et al are HIV infected children not on HAART (group 1 are HIV-infected on HAART for $ 4 months prior to vaccination);
d ‘‘other‘‘ group in Chandwani et al are HIV-infected vaccinated at 12 months only (group 1 are HIV-infected, vaccinated at 6 and 12 months);
e ‘‘other‘‘ group in Hilgartner et al are HIV-infected but unvaccinated (group 1 are HIV-infected, vaccinated);
f ‘‘other’’ group in Molyneaux et al are HIV-infected but unvaccinated (group 1 are HIV-infected, vaccinated);
S Safety outcomes: S0, no adverse event information reported; S1, explicit reporting on adverse events; S2, explicit reporting on serious adverse events; S2*, information based on ‘adverse event statement’;
S3, information on deaths reported;
P Progression of HIV: P1, information on progression of HIV-related disease reported;
I Immunogenicity outcomes: I0, immunogenicity either not reported or not assessed in this review; I1, seropositivity after vaccination reported; I2, seroconversion (seronegative before vaccination, seropositive after)
reported; I3, seroconversion (4-fold rise in titer) reported; I4, measure which might either be seropositivity after vaccination or seroconversion (seronegative before vaccination, seropositive after) is reported; I5 summary
immunological measure (e.g. geometric mean titer) reported for each group;
M Measles outcomes: M0, no information on occurrence of clinical measles, or unclear when or in which group clinical measles occurred; M1, reports explicitly on clinical measles after vaccination and numbers given by
group.
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Deaths after vaccination were reported in 7 studies [11, 23, 30,
34, 37, 40, 47]. No study stated that any deaths were related to
measles vaccination. In 1 study, it was stated that ‘‘no excess
of.death was found in association with vaccination’’ [39, p31].
The child described in the case report survived [6]. At least 75
deaths were reported among vaccinated HIV-infected children
(in 1 study, the number reported included unvaccinated children).
Details about hospitalizations were infrequently reported,
although 2 large prospective studies involving 1298 vaccinated
children reported that no hospitalizations were considered to
be measles vaccine related [11, 37]. One study reported a retro-
spective search for adverse events in the study cohort of 221
vaccinated children [34]. No serious adverse events were docu-
mented, and no cases of measles vaccine–related encephalitis
were reported to the regional authority during the period under
review. We found no studies directly comparing hospitaliza-
tion rates in vaccinated and unvaccinated HIV-infected chil-
dren. There was only 1 report of a serious adverse event
potentially associated with measles vaccination in which receipt
of measles vaccine could be confirmed. This was a nonfatal
illness resembling measles after vaccination of a 14-month-old
boy, in whom measles vaccine virus was sequenced from a
peripheral blood sample [6].
Measles Vaccine Immunogenicity
The majority of studies used enzyme-linked immunoassays to
determine measles antibody levels, but definitions and cutoff
points varied across studies (Figures 2–4). Two studies used
high-titer Edmonston-Zagreb vaccine, defined as potencies.4.7
log10 in children vaccinated at 6 months of age [23, 30]. These
studies were included, but we did not combine these results with
those from studies using standard-titer measles vaccine.
HIV-Infected Children. Levels of serological response
among HIV-infected children varied between studies, but there
was no clear pattern according to age at primary vaccination
(Figure 2). One study examined vaccination with standard-titer
measles vaccine at 6 and 9 months of age [11]; 59% (95% CI,
46%–71%) of children were seropositive after measles vaccina-
tion at 6 month of age, and 64% (95% CI, 49%–78%) were
seropositive after measles vaccination at 9 months of age. These
findings were consistent with results from 6 of 7 other studies of
HIV-infected children receiving primary measles vaccination at
9 months of age. After vaccination at$12 months of age, point
estimates ranged from 21% to 100%. No single factor (eg,
serological cutoff point, serological test used, and interval be-
tween vaccination and serology or receipt of HAART) appeared
to account for the variation between studies of vaccination at
9 or 12 months of age.
HIV-Exposed but Uninfected Children. Seropositivity after
vaccination with standard-titer measles vaccine at 6 months was
68% (95% CI, 62%–74%) [11]. After vaccination at 9 months of
age, point estimates of the proportion of seropositive children
ranged from 62% to 100% and were $90% in 4 of 8 studies
(Figure 3). After vaccination at 12 months of age, the proportion
of seropositive HIV-exposed but uninfected children was.90%
in all studies.
HIV-Unexposed Children. The pattern of serological res-
ponse by age at measles vaccination in HIV-unexposed children
was similar to that observed amongHIV-exposed but uninfected
children (Figures 3 and 4). Nine studies included a comparison
group of HIV-unexposed children (Figure 4). In the only study
using standard-titer measles vaccine at 6 months of age, 62%
(95% CI, 57%–66%) of children became seropositive [11]. The
proportion of seropositive children was higher after measles
vaccination at 9 months and was 100% after vaccination at 12
months in 2 small studies.
Comparisons Between Groups, According to HIV Infection
Status
In the only study using standard-titer measles vaccine at 6
months of age [11], there was no statistical evidence of a dif-
ference in serological response rates between HIV-infected and
children who were either HIV-exposed but uninfected or HIV-
unexposed (Table 3).
There were 2 studies that examined the effects of high-titer
measles vaccine given at 6 months of age [23, 30]. In HIV-
infected children in these studies, serological responses were
slightly higher than those in the study that used standard-titer
vaccine [11] (Figure 2). In comparative analyses, the serological
response after vaccination with standard-titer vaccine at 6
months of age in HIV-exposed but uninfected children was
slightly greater than in HIV-unexposed children (RR, 1.11;
95% CI, .99–1.24) [11], with similar results in high-titer studies
[23, 30].
After vaccination at 9 months, serological responses in HIV-
exposed but uninfected and HIV-unexposed groups were
similar (Table 3). Comparisons between HIV-infected and
HIV-exposed but uninfected children showed lower levels of
seropositivity in HIV-infected children at 12 months (RR, 0.61;
95% CI, .50–.73) [11]. No studies of children vaccinated at
$12 months of age reported a comparison between HIV-
exposed but uninfected and HIV-unexposed children.
Comparisons Between HIV-Infected Children, According to
Antiretroviral Therapy
We found 2 studies that assessed the impact of antiretroviral
therapy on serological responses to measles vaccine. Berkel-
hamer et al [19] examined HIV-infected children who had
previously received measles vaccine but had nonprotective an-
tibody levels. Seroconversion after revaccination was compared
between 14 children receiving HAART and 14 children who
were not receiving HAART (data from untreated children and
those receiving less potent regimens combined by authors).
More children seroconverted who were receiving HAART than
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Table 2. Information About Deaths and Serious Adverse Events in Studies Where These Outcomes Are Reported
Study
Measles
vaccinated
HIV-infected
children, n
Post-
vaccination
deaths in
HIV-infected
children, n
Time
observed
for deaths
Follow up
for deaths, n
(% lost to
follow up)
Deaths
reported
to be related
to vaccination
by investigators,a n
Post-
vaccination
SAE (other
than death)
in HIV-infected
children, n
Time
observed
for SAE
Follow up
for SAE other
than death, n
(% lost to
follow up)
SAE reported
to be related
to vaccination
by investigators, na
Aurpibul
2007 [17]
51 NR - - - 0 Unclear,
4 weeks?
51 (0%) 0
Cutts
1993 [23]
Unclear, 49 in
safety data, 34
in immunogenicity
data
9 Median
1.7 years
NR (NR%) NR 0 5-15 days 49 (NR%) NA
Echeverria
Lecuona
1996 [24]
10 NR - - - 0 NR 10 (NR%) 0
Embree
1989 [25]
Unclear, 61 children
of HIV infected
mothers
NR - - - 0 NR 61 (NR%) NA
Fernandez-
Ibieta
2007 [26]
55 NR - - - 0 NR 55 (NR%) NA
Frenkel 1
994 [27]
(& Frenkel
1992 [28])
10 NR - - - 0 10 (NR%) NA
Goon
2001 [6]
1 0 1 year 1 (0%) NA 1 1 year 1 (0%) 1
Helfand
2008 [11]
84 20 6 months 84 (19%b) 0 NER 4 weeks 83 (NR%) 0
Lepage
1992 [30]
43 15 18 months 43 (NR%) 0 0 18 months 43 (NR%)
43 (16%)
NA
Marczynska
2001 [33]
(substudy)
9 NR, but all
present at end
of follow up
3 months 9 (0%) NA 0 3 months 9 (0%) NA
McLaughlin
1988 [34]
70 Unclear,
41 deaths
amongst 221
measles
vaccinated
or unvaccinated
children
NR 70 (NR%) NR 1 possible,
but vaccination
not confirmed
NR 70 (NR%) 1 possible,
but vaccination
not confirmed
Molyneaux
1993 [36]
9 NR - - - NER, 1 where
unclear if
after vaccination
NR 9 (NR%) NR
S172
d
JID
2011:204
(S
u
p
p
l
1)
d
Sco
tt
et
al
Table 2. (Continued)
Moss
2007 [37]
66 28 27 months 66 (27.3%c) ‘‘not known’’ $ 1 (only given
as hospitalization
for measles-
like rash)
4 weeks 66 (,11%d) NR
Ndikyeze 1987 [38] 3 NR, but all
followed up
NR 3 (0%) NA 0 NR 3 (0%) NA
Oxtoby 1989 [39] Unclear, 37 in
immunogenicity
data
NER NR NR (NR%) NR NER NR NR (NR%) NR
Palumbo 1992 [40]
(& Hoyt 1992 [41])
92 vaccinated
during outbreak,
unknown
number in case finding
NR for outbreak,
2 in case finding e
NR NR (NR%) NR 0 NR NR (NR%) NA
Rudy 1994a&b [42] 13 (a) 12 (b) NR - - - 0 NR 13 (a) (NR%)
12 (b) (NR%)
NA
Thaithumyanon
2000 [47]
16 1 12 weeks 16 (6.25%f) 0 0 ‘‘short term’’ 16 (NR%) NA
NOTE. Included studies which are not listed in this table did not make any report on the occurrence or non-occurrence of deaths or Serious Adverse Events
NR, not reported; NER, not explicitly reported, only a vague statement made (e.g. ‘‘We did not find any increase in serious adverse events among HIV-infected children’’); NA, not applicable;
a numbers quoted relate to explicit statements
b based on 16 moved or withdrawn
c based on 18 moved, withdrawn or status unknown
d based on 7 moved or withdrawn at 1-6 months
e vaccinated 26 and 28m before measles
f based on 1 not completing
M
easles
V
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n
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those not receiving HAART (RR, 3.00; 95% CI, 1.02–8.80) de-
spite being slightly older and having more advanced HIV dis-
ease. Marczynska et al [33] compared 19 HIV-infected children
receiving HAART (mean age, 5.4 years) with 19 HIV-unexposed
children (mean age, 6 years). The seropositivity rate was lower in
revaccinated HIV-infected children than in HIV-unexposed
children (RR, 0.33; 95% CI, .18–.63).
DISCUSSION
This systematic review synthesized published evidence about the
safety and immunogenicity of measles vaccine in 39 studies
involving .1200 HIV-infected children. No study reported
deaths in HIV-infected children related to measles vaccine, and
we found only 1 case report of a serious adverse event possibly
related to measles vaccination. There was an absence of studies
directly comparing vaccinated with unvaccinated HIV-infected
children. Seropositivity after vaccination in HIV-infected chil-
dren did not improve as age at vaccination increased, unlike in
HIV-uninfected children.
The main strengths of our review were the systematic strategy
and broad search terms used to identify studies in a wide range
of databases and the rigorous methods used to extract and ap-
praise the data. The main limitation of this review was the need
to rely on observational data, apart from a small uncompleted
RCT [22]. The potential for confounding and bias should
therefore be considered when interpreting the results. There was
some statistical evidence that smaller trials were more likely to
show lower serological responses in HIV-infected children,
compared with HIV-exposed but uninfected children, which
could result from publication bias [12]. There might also be
systematic differences between smaller and larger trials. Trials of
children vaccinated at older ages tended to be smaller, and the
funnel plot asymmetry persisted in the group of trials among
Figure 2. Seropositivity or seroconversion after measles vaccination in HIV-infected children, absolute values, all studies. *Results are from the same
study after vaccination at 6 and 9 months of age; s-p, seropositivity; s-p?, unclear if those seropositive prior to vaccination are excluded; s-c1,
seroconversion from negative to positive; s-c2, seroconversion with 4-fold rise in titer; OD, optical density; change in OD, delta optical density ((mean of 2
viral antigen determinations - mean of 2 controls) x 1000); EU, ELISA units. a Studies where more than 75% of vaccinated children were available for
immunogenicity analyses b Studies where blood was drawn for measles serology less than 6 months after vaccination c Studies where children received
highly active antiretroviral therapy (HAART) c? Studies where it is not clear if children received HAART
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children vaccinated at 9 months but not at 12 months. Differ-
ences in types of serological assay and definitions of protective
levels were likely to affect the proportion of children seropositive
after vaccination in the HIV-infected group. We could not
assess these differences formally because of variability in the
assays.
We did not find evidence that serious adverse events due to
measles vaccination of HIV-infected children were common in
studies reporting this outcome. Generally poor reporting of
safety outcomes meant, however, that the incidence of adverse
events could not be estimated with confidence. Furthermore, the
sample sizes of prospective studies were insufficient to detect
rare events. The lack of studies directly comparing vaccinated
with unvaccinated HIV-infected children limited assessment of
whether adverse events occurring after vaccination were in
excess of the illnesses and deaths that would have occurred if
these children had not been vaccinated. We identified a case
report of a 14-month-old, HIV-infected boy who developed
fever and rash after receiving measles-mumps-rubella vaccine
that resolved after hospitalization without complications [6];
however, up to 5% of healthy individuals may experience fever
after measles vaccination and 2% may have a rash [3]. The only
documented case of fatal disease associated with measles vaccine
virus in an HIV-1-infected person was in a 20-year-old man in
the United States who died 15 months after receiving his second
dose of measles vaccine [5]. Ten months after measles vacci-
nation, he developed a giant cell pneumonia andmeasles vaccine
virus was identified in his lung.
In areas where measles virus is circulating [1], HIV-infected
and HIV-exposed but uninfected children could benefit from
earlier vaccination. Children born to HIV-infected women be-
come susceptible to measles virus infection at a younger age than
do children of uninfected mothers [3], because placental transfer
of maternal antibodies is impaired in HIV-1–infected women
Figure 3. Seropositivity or Seroconversion after Measles Vaccination in HIV-Exposed but Uninfected Children, Absolute Values, All Studies.* Results
are from the same study after vaccination at 6 and 9 months of age; s-p, seropositivity; s-p?, unclear if those seropositive prior to vaccination are
excluded; s-c1, seroconversion from negative to positive; s-c2, seroconversion with 4-fold rise in titer; OD, optical density; change in OD, delta optical
density ((mean of 2 viral antigen determinations - mean of 2 controls) 3 1000); EU, ELISA units. a Studies where more than 75% of vaccinated children
were available for immunogenicity analyses b Studies where blood was drawn for measles serology less than 6 months after vaccination
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[50]. Our findings suggest that measles vaccine could be given to
all infants of HIV-infected mothers at 6 months, even if the
child’s HIV infection status is not known. Although only 1 study
used standard-titer measles vaccine at this age, it was a large
well-conducted prospective study [11]. Two studies using
high-titer measles vaccine at 6 months of age produced results
consistent with this pattern [23, 30]. Although this vaccine is no
longer used, these studies provide supportive evidence of the
immunogenicity of early measles vaccination in HIV-infected
children. The level of seropositivity in HIV-infected children
vaccinated at 6 months of age was comparable to that achieved in
HIV-infected children receiving primary measles vaccination at 9
months in several other studies [32, 39, 42, 47]. In addition, the
response to measles vaccine at 6 months among HIV-exposed
but uninfected children was slightly higher than that in HIV-
unexposed children [11]. Lower levels of maternal antibody in
HIV-exposed but uninfected children [50] might allow for a bet-
ter immunological response to earlier doses of measles vaccine.
The results of this review have implications for measles con-
trol strategies in areas with a high prevalence of HIV infection.
The 2009 WHO position paper on measles vaccination, sup-
ported by the results of this review, now states that the first dose
of measles vaccine can be given as early as 6 months in areas
where there is a high incidence of both measles and HIV in-
fection [7]. This recommendation means that HIV infection
status does not have to be known before early vaccination. There
are opportunities to provide measles vaccine at 6 and 9 months
to children of mothers who are known to be HIV infected and
are receiving care in Prevention of Mother-To-Child Trans-
mission Plus or antiretroviral treatment programs. Supple-
mentary immunization activities and programs to accelerate
coverage of routine measles vaccination would also increase
levels of indirect protection to susceptible HIV-infected chil-
dren. There are some priorities for both public health research
and practice. Large studies of the effects of expanded access to
HAART on susceptibility to measles and serological responses to
measles vaccination should be conducted, and the assessment
and reporting of measles vaccine safety need to be improved. In
summary, measles vaccines appear to be safe in HIV-infected
children, but evidence is limited. Because of the potentially in-
creased case-fatality associated with measles in HIV-infected
children, children of HIV-infected mothers may benefit from
initial vaccination at 6 months in regions with high measles
burden, regardless of the child’s HIV status.
Figure 4. Seropositivity or Seroconversion after Measles Vaccination in HIV-Unexposed Children, Absolute Values, All Studies. * Results are from the
same study after vaccination at 6 and 9 months of age; s-p, seropositivity; s-p?, unclear if those seropositive prior to vaccination are excluded; s-c1,
seroconversion from negative to positive; s-c2, seroconversion with 4-fold rise in titer; OD, optical density; change in OD, delta optical density ((mean of 2
viral antigen determinations - mean of 2 controls) 3 1000); EU, ELISA units. a Studies where more than 75% of vaccinated children were available for
immunogenicity analyses b Studies where blood was drawn for measles serology less than 6 months after vaccination
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